Muralidharan, Kumar Kandadi http://orcid.org/0000-0002-7879-5769
Kowalski, Kenneth G.
Tong, Xiao
Haeberlein, Samantha Budd
Rajagovindan, Rajasimhan
Nestorov, Ivan
Funding for this research was provided by:
Biogen
Article History
Received: 27 September 2021
Accepted: 16 December 2022
First Online: 4 January 2023
Change Date: 4 March 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10928-023-09852-0
Declarations
:
: Kumar Kandadi Muralidharan, Xiao Tong, Samantha Budd Haeberlein, and Ivan Nestorov are employees of and hold stock and/or stock options in Biogen (Cambridge, MA, USA). Kenneth G. Kowalski was a paid consultant of Biogen. Rajasimhan Rajagovindan is a former employee of Biogen and is currently employed by Vigil Neuroscience.
: All studies were sponsored by Biogen and were approved by Ethics Committees or Institutional Review Boards at each site and conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonization Guideline for Good Clinical Practice. All patients provided written informed consent. An independent data monitoring committee monitored the conduct of the trials, routinely assessed safety, and reviewed futility analysis results.
: Written informed consent was obtained from all subjects.